It has been argued that in certain conditions there may even be a lack of real clinical benefit from vascular normalization, e.g. for the use of anti-VEGF antibody therapy in the case of cerebral tumors where normalization may reduce drug delivery by helping the re-establishment of brain microvasculature which is normally characterized by reduced permeability50. This evidence concerns the gene VEGFA and neoplasm of cerebral hemisphere.